Туберкулез и болезни легких

Расширенный поиск

Новая коронавирусная инфекция

Полный текст:


В обзоре проанализировано 59 источников литературы, в которых отражены известные на данный момент аспекты этиологии, патогенеза, диагностики и лечения заболевания COVID-19, вызванного коронавирусом SARS-CoV-2.

Авторы заявляют об отсутствии у них конфликта интересов.

Об авторах

Е. И. Веселова
ФГБУ «Национальный медицинский исследовательский центр фтизиопульмонологии и инфекционных заболеваний» МЗ РФ

Веселова Елена Игоревна научный сотрудник отдела инфекционной патологии

А. Е. Русских
ФГБУ «Национальный медицинский исследовательский центр фтизиопульмонологии и инфекционных заболеваний» МЗ РФ
Русских Анастасия Евгеньевна научный сотрудник

Г. Д. Каминский
ФГБУ «Национальный медицинский исследовательский центр фтизиопульмонологии и инфекционных заболеваний» МЗ РФ
Каминский Григорий Дмитриевич доктор медицинских наук, руководитель отдела инфекционной патологии

О. В. Ловачева
ФГБУ «Национальный медицинский исследовательский центр фтизиопульмонологии и инфекционных заболеваний» МЗ РФ
Ловачева Ольга Викторовна доктор медицинских наук, профессор, главный научный сотрудник

А. Г. Самойлова
ФГБУ «Национальный медицинский исследовательский центр фтизиопульмонологии и инфекционных заболеваний» МЗ РФ
Самойлова Анастасия Геннадьевна доктор медицинских наук, первый заместитель директора

И. А. Васильева
ФГБУ «Национальный медицинский исследовательский центр фтизиопульмонологии и инфекционных заболеваний» МЗ РФ
Васильева Ирина Анатольевна доктор медицинских наук, профессор, директор

Список литературы

1. Арсеньев А. Новые рычаги опухолевого сопротивления: Lag-3, Tim-3, TIGIT. 2019.

2. Электронный ресурс. –

3. Abdulamir A. S., Hafidh R. R. The possible immunological pathways for the variable immunopathogenesis of COVID-19 infections among healthy adults, elderly and children // Electron. J. Gen. Med. ‒ 2020. ‒ Vol. 17, № 4. ‒ Р. em202.

4. Benetti E. et al. ACE2 variants underlie interindividual variability and susceptibility to COVID-19 in Italian population. – medRxiv. 03.04.2020.

5. Caly L., Druce J. D., Catton M. G., Jans D. A., Wagstaff K. M. The FDA approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro // Antiviral. Research. ‒ 2020.

6. Cao B., Wang Y., Wen D., Liu W., Wang J., Fan G. et al. A trial of Lopinavir-Ritonavir in adults hospitalized with severe Covid-19 // New Engl. J. Med. ‒ 2020.

7. Cao Y. C., Deng Q. X., Dai S. X. Remdesivir for Severe Acute Respiratory Syndrome Coronavirus 2 Causing COVID-19: An Evaluation of the Evidence // Travel. Med. Infect. Dis. ‒ 2020. ‒ Apr 2; 101647.

8. Chen W., Lan Y., Yuan X. et al. Detectable 2019-nCoV Viral RNA in blood is a strong indicator for the further clinical severity // Emerg. Microbes. Infect. ‒ 2020. ‒ Vol. 9, № 1. ‒ Р. 469-473.

9. Cortegiani A., Ingoglia G., Ippolito M., Giarratano A., Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19 // J. Crit. Care. ‒ 03.2020.

10. Diao B., Wang C., Tan Y., Chen X. et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). medRxiv 2020.

11. Dolhnikoff M., Duarte-Neto A. N., de Almeida Monteiro R. A., Ferraz da Silva L. F. Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19.

12. Elfiky A. A. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19 // Life Sci. ‒ 2020.

13. Fahmi M., Kubota Y., Ito M. Nonstructural proteins NS7b and NS8 are likely to be phylogenetically associated with evolution of 2019-nCoV // Infect. Genet. Evol. ‒ 2020.

14. Fang L., Karakiulakis G., Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? // Lancet. ‒ 11.03.2020.

15. Forster P., Forster L., Renfrew C., Forster M. Phylogenetic network analysis of SARS-CoV-2 genomes. ‒ PNAS 08.04.2020.

16. Gautret et al. Hydroxychloroquine and azithromycin as a treatment of COVID‐19. 2020.

17. Gautret P., Lagier J. C., Parola P., Hoang V. T. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study // Travel. Med. Infect. Dis. ‒ 2020. ‒ Apr 11:101663.

18. Guo L., Ren L., Yang S., Xiao M. Profiling early humoral response to diagnose Novel Coronavirus Disease (COVID-19) // Clin. Infect. Dis. ‒ 2020. ‒ 21.03.2020. pii: ciaa310.

19. Han H., Luo Q., Mo F., Long L., Zheng W. SARS-CoV-2 RNA more readily detected in induced sputum than in throat swabs of convalescent COVID-19 patients // Lancet Infect. Dis. ‒ 12.03.2020. pii: S1473-3099(20)30174-2.

20. Hoffmann M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. ‒ Cell. 2020.

21. Huang P. et al. Use of Chest CT in combination with negative RT-PCR assay for the 2019 Novel Coronavirus but high clinical suspicion // Radiology. ‒ 12.02.2020.

22. Kim D., Lee J. Y., Yang J. S., Kim J. W., Kim V. N., Chang H. The architecture of SARS-CoV-2 transcriptome. ‒ bioRxiv. 15.03.2020.

23. Lan L., Xu D., Ye G., Xia C et al. Positive RT-PCR test results in patients recovered from COVID-19 // JAMA. ‒ 27.02.20.

24. Lin L., Lu L., Cao W., Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection ‒ a review of immune changes in patients with viral pneumonia // Emerg. Microbes Infect. ‒ 2020. ‒ Mar 20. ‒ Р. 1-14.

25. Pan F., Ye T., Sun P., Gui S. et al. Time course of lung changes on chest CT during recovery from 2019 Novel Coronavirus (COVID-19) pneumonia // Radiology. ‒ 2020.

26. Pan Y., Zhang D., Yang P., Poon L. M., Wang Q. Viral load of SARS-CoV-2 in clinical samples // Lancet. ‒ 24.02.2020.

27. Paraskevis D. et al. Full-genome evolutionary analysis of the Novel Coronavirus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event // Infect. Genet. Evol. ‒ 28.01.2020.

28. Pradhan P. et al. Uncanny similarity of unique inserts in the 2019-nCoV spike protein to HIV-1 gp120 and Gag. ‒ bioRhiv. 30.01.2020.

29. Qi F., Qian S., Zhang S., Zhang Z. Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses // Biochem. Biophys. Res. Commun. ‒ 18.03.2020.

30. Richardson P., Griffin I., Tucker C., Smith D. et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease // Lancet. ‒ Vol. 395(10223). ‒ 2020.

31. Salata C., Calistri A., Parolin C., Palù G. Coronaviruses: a paradigm of new emerging zoonotic diseases // Pathog. Dis. ‒ 2019. Dec. ‒ Vol. 77, № 9.

32. Shakiba Y. Application of desferal to treat COVID-19.

33. Shen C. et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma // JAMA. ‒ 2020.

34. Sheridan C. Fast, portable tests come online to curb coronavirus pandemic // Nat. Biotechnol. ‒ 2020. ‒ Mar 23.

35. Stebbing J. et al. COVID-19: Combining antiviral and anti-inflammatory treatments // Lancet Infect. Dis. ‒ 2020.

36. Sun P., Lu X., Xu C., Wang Y., Sun W., Xi J. CD-sACE2 inclusion compounds: an effective treatment for Corona Virus Disease 2019 (COVID-19) // J. Med. Virol. ‒ 31.03.2020.

37. Tang N., Li D., Wang X., Sun Z. Abnormal Coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia // J. Thromb. Haemost. ‒ 2020. ‒ Vol. 18, № 4. ‒ Р. 844-847.

38. Veljkovic V., Vergara-Alert J., Segalés J., Paessler S. Use of the informational spectrum methodology for rapid biological analysis of the Novel Coronavirus 2019-nCoV: prediction of potential receptor, natural reservoir, tropism and therapeutic/vaccine target. F1000 Research. 31.01.2020.

39. Wan S., Xiang Y., Fang W., Zheng Y. et al. Clinical features and treatment of COVID-19 patients in northeast chongqing // J. Med. Virol. ‒ 21.03.2020.

40. Wang M., Cao R., Zhang L., Yang X. Remdesivir and chloroquine effectively inhibit the recently emerged Novel Coronavirus (2019-nCoV) in vitro // Cell Research. ‒ 04.02.2020.

41. Wang Q., Qiu Y., Li J. Y., Zhou Z. J. et al. A unique protease cleavage site predicted in the spike protein of the Novel Pneumonia Coronavirus (2019-nCoV) potentially related to viral transmissibility // Virol. Sin. ‒ 2020 Mar 20.

42. Wang W., Xu Y., Gao R., Lu R et al. Detection of SARS-CoV-2 in different types of clinical specimens // JAMA. ‒ 11.03.2020.

43. Wenzhong L., Hualan L. COVID-19: Attacks the 1-Beta chain of hemoglobin and captures the porphyrin to inhibit human heme metabolism. ‒ ChemRxiv. 13.04.2020.

44. Wit E., Feldmann F., Cronin J., Jordan R. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection // PNAS. ‒ 24.03.2020. ‒ Vol. 117, № 12. ‒ Р. 6771-6776.

45. Wu A., Peng Y., Huang B., Ding X. et al. Genome composition and divergence of the Novel Coronavirus (2019-nCoV) originating in China // Cell. Host. Microbe. ‒ 07.02.20.

46. Xiao A. T., Tong Y. X., Gao C., Zhu L. Dynamic profile of RT-PCR findings from 301 COVID-19 patients in Wuhan, China: a descriptive study // J. Clin. Virol. ‒ 2020. ‒ Apr 11.

47. Xiong Y. et al. Clinical and high-resolution CT features of the COVID-19 infection: comparison of the initial and follow-up changes // Invest. Radiol. ‒ 2020. ‒ AJR Am. J. Roentgenol. ‒ 2020.

48. Yamamoto N., Matsuyama S., Hoshino T., Yamamoto N. Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro. ‒ bioRxiv. 2020.

49. Yang M. Cell pyroptosis, a potential pathogenic mechanism of 2019-nCoV infection // SSRN:, 29.01.2020.

50. Yao X., Ye F., Zhang M., Cui C., Huang B., Niu P. et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) // Clin. Infect. Dis. ‒ 2020.

51. Yi H. 2019 novel coronavirus is undergoing active recombination // Clin. Infect. Dis. ‒ 2020.

52. Yu F., Yan L., Wang N., Yang S. Quantitative detection and viral load analysis of SARS-CoV-2 in infected patients // Clin. Infect. Dis. ‒ 28.03.2020, pii: ciaa345.

53. Zhang L., Lin D., Kusov Y., Nian Y. et al. Alpha-ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication Structure-based design, synthesis, and activity assessment // J. Med. Chem. ‒ 11.02.2020.

54. Zhang T., Wu Q., Zhang Z. Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak // Curr. Biol. ‒ 13.03.2020.

55. Zhang W., Zhao Y., Zhang F., Wang Q. et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The experience of clinical immunologists from China // Clin. Immunology. – 2020. – Р. 108393.

56. Zhao J. et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. – 2020.

57. Zhao W., Zhong Z., Xie, Yu Q., Liu J. Relation between chest CT findings and clinical conditions of coronavirus disease (COVID-19) pneumonia: A multicenter study.

58. Zhao Y., Zhao Z., Wang Y., Zhou Y., Ma Y., Zuo W. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. ‒ bioRxiv. 26.01.2020.

59. Zou L., M. Sc. et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients // New Engl. J. Med. ‒ 20.02.20.


Для цитирования:

Веселова Е.И., Русских А.Е., Каминский Г.Д., Ловачева О.В., Самойлова А.Г., Васильева И.А. Новая коронавирусная инфекция. Туберкулез и болезни легких. 2020;98(4):6-14.

For citation:

Veselova E.I., Russkikh A.E., Kaminskiy G.D., Lovacheva O.V., Samoylova A.G., Vasilyeva I.A. Novel coronavirus infection. Tuberculosis and Lung Diseases. 2020;98(4):6-14. (In Russ.)

Просмотров: 1647

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.

ISSN 2075-1230 (Print)
ISSN 2542-1506 (Online)